Deferasirox and Promacta drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Deferasirox (deferasirox) and Promacta (eltrombopag olamine). Common drug interactions include death among males.
The phase IV clinical study analyzes what interactions people have when they take Deferasirox and Promacta. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.
What is Deferasirox?
Deferasirox has active ingredients of deferasirox. eHealthMe is studying from 2,641 Deferasirox users. Check the latest studies of Deferasirox.
What is Promacta?
Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,758 Promacta users. Check the latest studies of Promacta.
13 people who take Deferasirox and Promacta together, and have interactions are studied.
What are the common drug interactions of Deferasirox and Promacta, by gender? *:
female:
n/a
male:
- Death
- Pyrexia (fever)
- Haematocrit decreased
- Haemoglobin decreased
- Haptoglobin decreased
- Hepatitis b
- Iron overload
- Loss of consciousness
- Neutropenia (an abnormally low number of neutrophils)
- Platelet count decreased
What are the common drug interactions of Deferasirox and Promacta, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
- Haemoglobin decreased
- Haptoglobin decreased
- Hepatitis b
- Iron overload
- Neutropenia (an abnormally low number of neutrophils)
- Platelet count decreased
- Pyrexia (fever)
- Reticulocyte count increased
- Serum ferritin increased
- Serum sickness (hypersensitivity reaction that results from the injection of heterologous or foreign protein or serum)
50-59:
- Death
60+:
- Death
- Pyrexia (fever)
What are the existing conditions these people have? *
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 4 people, 30.77%
- Thrombocytopenia (decrease of platelets in blood): 1 person, 7.69%
- Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 7.69%
- Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 1 person, 7.69%
- Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 1 person, 7.69%
- Aplastic Anemia: 1 person, 7.69%
- Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 7.69%
* Approximation only. Some reports may have incomplete information.
Do you take Deferasirox and Promacta?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Deferasirox (2,641 reports)
- Promacta (17,758 reports)
Browse all drug interactions of Deferasirox and Promacta:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Deferasirox:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Promacta:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Deferasirox and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Promacta and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on deferasirox and eltrombopag olamine (the active ingredients of Deferasirox and Promacta, respectively), and Deferasirox and Promacta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
No recent updates.